Pfizer, Inc. (NYSE:PFE) was the target of unusually large options trading on Tuesday. Stock investors acquired 760 put options on the company. This is an increase of approximately 125% compared to the average daily volume of 338 put options.

Shares of Pfizer (NYSE:PFE) traded up 1.309% on Tuesday, hitting $33.655. The company had a trading volume of 13,903,521 shares. The company has a market capitalization of $200.85 billion, a price-to-earnings ratio of 28.329 and a beta of 1.02. The stock’s 50-day moving average is $32.71 and its 200 day moving average is $33.05. Pfizer has a 52 week low of $29.83 and a 52 week high of $37.39.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The company had revenue of $12.78 billion for the quarter, compared to analyst estimates of $13.09 billion. During the same period last year, the company earned $0.67 earnings per share. Pfizer’s quarterly revenue was down 1.7% compared to the same quarter last year. Equities analysts expect that Pfizer will post $2.55 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 1st. Shareholders of record on Friday, May 12th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.85%. The ex-dividend date of this dividend was Wednesday, May 10th. Pfizer’s payout ratio is currently 108.48%.

A number of equities analysts have weighed in on PFE shares. Barclays PLC set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Thursday, March 16th. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $34.97 price target for the company. in a research note on Thursday, February 23rd. Jefferies Group LLC restated a “neutral” rating and set a $35.00 price target (up from $34.00) on shares of Pfizer in a research note on Thursday, April 13th. BMO Capital Markets restated a “hold” rating and set a $33.00 price target on shares of Pfizer in a research note on Tuesday, March 21st. Finally, Sanford C. Bernstein set a $35.00 price target on Pfizer and gave the company a “buy” rating in a research note on Monday, March 13th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $37.32.

A number of hedge funds have recently modified their holdings of the stock. Atlantic Trust LLC raised its stake in shares of Pfizer by 1.3% in the first quarter. Atlantic Trust LLC now owns 22,870 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 300 shares during the last quarter. Clearbridge Investments LLC raised its stake in shares of Pfizer by 0.5% in the first quarter. Clearbridge Investments LLC now owns 10,914,872 shares of the biopharmaceutical company’s stock valued at $373,398,000 after buying an additional 54,076 shares during the last quarter. TrueNorth Inc. raised its stake in shares of Pfizer by 7.5% in the first quarter. TrueNorth Inc. now owns 25,397 shares of the biopharmaceutical company’s stock valued at $869,000 after buying an additional 1,782 shares during the last quarter. Laurel Wealth Advisors Inc. raised its stake in shares of Pfizer by 10.1% in the first quarter. Laurel Wealth Advisors Inc. now owns 56,324 shares of the biopharmaceutical company’s stock valued at $1,926,000 after buying an additional 5,180 shares during the last quarter. Finally, Perigon Wealth Management LLC raised its stake in shares of Pfizer by 3.2% in the first quarter. Perigon Wealth Management LLC now owns 67,614 shares of the biopharmaceutical company’s stock valued at $2,313,000 after buying an additional 2,124 shares during the last quarter. 70.80% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/06/20/pfizer-target-of-unusually-large-options-trading-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.